2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow BioCis Pharma Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis Cis-UCA 2.5% emulsion cream, Cis-UCA 5% emulsion cream, Placebo for cis-UCA emulsion cream - Atopic Dermatitis | Phase 2 | Completed | BioCis Pharma Ltd | 159 | 2011-03-01 | 2012-06-21 |
| Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer cis-UCA solution - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | BioCis Pharma Ltd | 12 | 2009-10-01 | 2012-11-12 |
Dermatitis, Atopic (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
Ointments (1) · Tacrolimus (1)
Finland (2)
Juha Peltonen, MD (1) · Sakari Reitamo, Professor (1)
2009 (1)